VTX958

Even with phase 2 success, Ventyx halts TYK2 inhibitor, sending stock plummeting 70%
Fierce Biotech
Tue, 11/7/23 - 10:00 am
Ventyx Biosciences
clinical trials
TYK2 inhibitors
VTX958
psoriasis
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Tue, 08/16/22 - 12:22 pm
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib